Area of research
Hematology · Pathology and Forensic Medicine
Research interest
Research interests include Multiple Myeloma Research and Treatments, Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, and Cancer Treatment and Pharmacology.
CD74-Targeted Cathepsin-Inhibitor Antibody–Drug Conjugate Triggers Apoptosis in DLBCL
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
Ethnic variation in medical and lifestyle risk factors for B cell non-Hodgkin lymphoma: A case-control study among Israelis and Palestinians
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and immune response to hepatitis B
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A Phase <scp>II</scp> trial of Belinostat ( <scp>PXD</scp> 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma
Susceptibility Loci Associated with Specific and Shared Subtypes of Lymphoid Malignancies